Loading organizations...

§ Private Profile · New York City, NY, USA
Personalized immunotherapy combining tumor neoantigens and peptides.
Nema Health offers expert online trauma therapy, specializing in PTSD treatment through a comprehensive care model delivered by licensed therapists.
Nema Health has raised $20.2M across 3 funding rounds.
Nema Health has raised $20.2M in total across 3 funding rounds.
Nema Health has raised $20.2M in total across 3 funding rounds.
Nema Health's investors include BCN Peptides, CDTI Innvierte, EconomistesBAN, MedAngels, Deerfield Management, Health Velocity Capital, Northpond Ventures, Section 32, .406 Ventures.
Nema Health is a virtual healthcare company offering evidence-based, intensive outpatient treatment for trauma and PTSD, primarily through Cognitive Processing Therapy (CPT) delivered remotely via daily therapy sessions, psychiatric medication management, and peer support from fellow trauma survivors.[1][2][3] It serves trauma survivors across various experiences like sexual assault, domestic violence, gun violence, and natural disasters, solving the problem of limited access to specialized, rapid-relief PTSD care by providing clinical improvement for 91% of patients and remission for 82% after just 4-6 weeks.[2][3] Founded in 2020 and launched in 2023, the company operates in eight states (New Jersey, New York, Connecticut, California, Massachusetts, Pennsylvania, Florida, and Illinois), is in-network with multiple insurers, and has raised $18.6 million total funding, including a $14.5 million Series A in early 2025 led by Deerfield Management to fuel geographic expansion and new services.[2][3][4]
Nema Health was founded in 2020 by Dr. Sofia Noori, a Yale-trained psychiatrist, clinical instructor in Yale's Department of Psychiatry, and trauma survivor, shortly after her residency graduation in 2021; she serves as CEO and co-founder alongside COO Mariam Malik and Medical Director Dr. Isobel Rosenthal.[1][2][4] The idea emerged from Noori's recognition that 80% of people endure trauma in their lifetimes (e.g., from violence, accidents, war, or disasters), yet 20% develop PTSD, with insufficient evidence-based options available; she aimed to deliver rapid, peer-led CPT—the most effective PTSD treatment—to enable long-term healing and joyful lives.[2][3] Early traction built through a physician- and survivor-led model, culminating in a 2023 launch across initial states, a $4.1 million seed round in 2024 led by Optum Ventures and .406 Ventures, and the recent Series A for broader rollout.[3][4]
Nema Health rides the telehealth boom in mental health, accelerated by post-pandemic demand for virtual behavioral care amid clinician shortages and rising trauma from violence, disasters, and crises, positioning it in the $100B+ digital health market.[2][3][4] Its timing aligns with insurer shifts toward value-based care for high-impact conditions like PTSD, where traditional outpatient models fail on speed and retention; market forces like expanded coverage and VC interest (e.g., from Deerfield, CVS Ventures) favor scalable, outcomes-proven platforms.[3][4] By prioritizing CPT and peer support, Nema influences the ecosystem toward specialized, measurement-driven trauma tech, potentially setting standards for peer integration and rapid remission in a field crowded with generalist apps.
Nema Health is poised for national scale in 2025, using its Series A to enter more states, secure broader payer partnerships, and deepen offerings like new therapies or tools, building on 90%+ patient success to claim leadership in trauma care.[3][4] Trends like AI-enhanced personalization, hybrid care models, and climate/war-driven trauma surges will propel growth, while its clinician-survivor ethos could evolve influence toward policy advocacy for PTSD insurance mandates. As virtual specialists disrupt fragmented mental health, Nema exemplifies how targeted tech delivers measurable healing where general solutions fall short—transforming survivor lives at population scale.[2][3]
Nema Health has raised $20.2M across 3 funding rounds. Most recently, it raised $1.2M Grant / Seed in March 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 13, 2026 | $1.2M Grant | — | BCN Peptides, CDTI Innvierte, Economistesban, MedAngels | Announced |
| Oct 1, 2024 | $15M Series A | Deerfield Management | Health Velocity Capital, Northpond Ventures, Section 32 | Announced |
| Nov 1, 2023 | $4M Seed | .406 Ventures | — | Announced |